By ZTEC100 Editorial Team | November 2026
For the last three years, the healthcare and insurance industry has been talking about “artificial intelligence” as a promise. But in 2026, the promise has quietly been integrated into their operational structure. The most significant developments are no longer a flashy robot or a pilot program launched for the sake of a press release, but an automatic prior authorization that clears in under ninety seconds, an actuarial risk model that flags risk without human intervention, and a clinical network that connects a surgeon with a nutritionist for follow-up after surgery, through one single AI-mediated workflow.
This abridged review of the most recent developments in three convergent areas — health insurance, clinical science, and the legislation that unites them — will map out how far along the industry has come as the year 2026 draws to a close.
The State of Play: AI Moves from Pilot to Production
In the past, the Society of Actuaries collected the most complete information on the subject of AI in the health care sector, at a round table which it held in late 2025, and published in January 2026. It found that the pace of introduction varied, and that most of the participants in the discussion believed that, while the technology could be used more and more to increase data analysis, speed up administrative processes, and support decision-making in underwriting, rates, and health management, the panel also found that these developments needed to operate within strong governance frameworks, and that transparency and clear professional accountability were necessary.
The precautions are not theoretical. SCOR, the international reinsurance company, published in May the results of its experiment with an AI Assistant for the operations of underwriting and claims. It now processes over one million pages of documents every month in the main markets, but the result is surprisingly counter-intuitive: the time to process cases was initially increased rather than decreased, because employees had to take time to check the texts that the machine had read against the original text. SCOR’s lesson was that the expected benefits of artificial intelligence will not appear right away and that the risk of abandoning the project too soon if the expected immediate results are not met, consists in not giving up too quickly.
It is true that automation in the health insurance industry is more nuanced than the extremes of skepticism and hype would have us believe. Of the two solution categories we have examined in detail at Research2Guidance, based on an analysis of the twenty largest health insurance companies in the U.S. and Europe, only the automation of prior authorizations is mature and arguably the most important of them. Florida Blue auto-approves 78% of its authorizations in less than 90 seconds. Optum’s Digital Prior Auth reports a 96% first-time approval rate across more than 500 million transactions. Elevance has reduced the work of prior authorization by roughly 70%.
For the moment, intelligent data processing for submitting claims is still a step behind but is well past the pilot stage; the annual savings on claims automation alone at HCSC are approximately $1.6 million. Agentic workflow orchestration, generative underwriting, and AI-driven payment integrity at scale remain mostly internal projects with limited public disclosure. In the field of fraud, waste, and abuse detection and in care management, the gap between “press-release” AI and operationally embedded AI is greatest.
It is equally true that the geographic difference is revealing. US private insurers have moved on to consumer-facing generative assistants and the automation of the authorization process, while the European statutory and national payers have been focusing on the governance and the technological foundations, and prior-authorization AI is largely absent from the European payer set. For health technology suppliers the message is clear: the new opportunity is not a member assistant. It is fraud analytics, back-office automation, care management support, and interoperability middleware.
The Clinical Front: Validation, Not Just Innovation
But while insurance companies are busy automating the back office, the clinical side of medical artificial intelligence is also undergoing its own transformation. At the China International Import Expo in Shanghai at the beginning of November, Roche brought a one-stop AI-based research tool to assist doctors with intelligent topic selection, literature review, and solution generation, along with a digital remote patient management system for continuous home health management. Haier’s health business unit Incaier launched an AI strategy built around a central “brain”, with more than 450 AI-native applications already developed. Australian biopharmaceutical company CSL signed an agreement with Peking Union Medical College Hospital to explore AI-assisted diagnosis of hereditary angioedema, a rare disease.
The most striking data point from the expo came from Philips’ 2026 China edition of its Future Health Index report, which states that 95% of Chinese clinical healthcare workers surveyed have already shifted or will shift their focus toward higher-value clinical work; 81% of Chinese patients believe that learning to use AI will become an essential skill for managing their health, well above the 59% global average; and 69% of Chinese healthcare workers believe AI helps improve patient health outcomes.
AI-driven virtual triage is becoming the first point of contact in many health systems, completing the preliminary intake before referral to the staff. Agentic AI takes over administrative tasks such as billing, coding, and telemedical documentation. But the IEEE standards association warns that reported efficiency gains vary widely, and that they often lack transparency about error rates. Many patients, in moments of anxiety, are frustrated and even uneasy at having to communicate with a non-human system, and wonder whether its answers are correct.
At the China International Import Expo, Intuitive Fosun launched a digital platform called My Intuitive to connect products, services, and clinical scenarios across the surgical journey. For cancer patients, the challenge extends far beyond a single operation or hospital stay, and care has to continue after the patient leaves the hospital. Yingkang Life demonstrated an AI-powered tumor full-cycle management platform that bridges in-hospital treatment and out-of-hospital health management. When a patient reported poor appetite, the AI assistant asked follow-up questions about symptom duration, accompanying discomfort, and weight changes, then organized the information for a nutritionist and physician to review. The AI handles daily communication and information organization; the doctor makes the professional judgment about the patient’s condition.
This division of work between human and machine is emerging as the model of consensus, which is interestingly the model that actuaries and insurers independently arrived at. The SOA round table stressed that trust and validation of AI remain central, and actuaries expressed caution about using its output without proper verification and human review. Moreover, hallucinations and non-deterministic behaviour in large language models are identified as significant concerns.
The Regulatory Squeeze: Fragmentation and Its Consequences
In 2026, the governing legislation for health-care AI is more splintered than a year earlier, but paradoxically more manageable for those who operate according to principles rather than any single law. The European Union’s “Digital Omnibus on AI”, which came into force in July 2026, postponed the high-risk requirements originally set for August 2026 to December 2027 for stand-alone systems and August 2028 for AI embedded in products and medical devices. The obligations were not softened, only postponed — an honest admission that the world’s most developed regulatory mechanism is straining to keep pace with the technology.
In the United States, the change has been philosophical rather than administrative. The current administration has pursued an expressly deregulatory national AI policy, including efforts to pre-empt the growing body of state AI legislation. The FDA has already authorized over a thousand AI-enabled medical devices, and is narrowing its oversight of lower-risk digital health tools while relying more heavily on post-market surveillance.
Elsewhere, regulation is arriving for the first time. South Korea’s AI Framework Act took effect in January 2026, and became the first comprehensive AI statute in the Asia-Pacific region, imposing transparency, impact assessment, and human oversight obligations on “high-impact” AI systems in healthcare, and demanding labeling of generative AI outputs. China continues its distinctive path of binding, sector-specific rules — requiring the registration of algorithms, generative models, and content labeling — while state policy drives some of the most aggressive hospital-level AI deployment in the world.
The European product liability directive, which member states are required to transpose by December 2026, specifically extends strict liability to software and artificial intelligence, eases the burden of proof for claimants faced with opaque technology, and expands the range of economic operators who can be held liable. For multinational developers and investors, this means a compliance map that requires a good knowledge of jurisdictions. As artificial intelligence becomes more capable and autonomous, the range and number of potential defendants grows from the physician and hospital to the manufacturer, the supplier, the developer, and the deployer.
The governance problems in the insurance industry are equally compelling. MoneyGeek’s research, citing the National Association of Insurance Commissioners, found that nearly one in three health insurers do not test their AI models for racial bias. The iFHP Global Benchmark Report 2026 found that member-facing applications remained cautious out of concerns over trust and compliance, while operational and support functions tend to be furthest ahead, where use cases are clearer and risks are easier to manage.
The Next Frontier: Invisible AI and the Integration Imperative
The main strategic insight of 2026 is that the next wave of AI in health plans will not be defined by who has launched the most visible virtual assistant, but by who manages to make the AI invisible, integrating it into the underlying processes that decide whether a claim is paid, whether an authorization clears, or whether a member ever has to call.
Health care took centre stage at CES 2026, with companies displaying the latest in “household medicine.” A Korean firm showed a future home where the smart system could check a family member’s brainwaves for stress, check their skin, monitor their moods and energy, examine their blood pressure and weight, and, based on their genetic makeup, suggest a health regime tailored to each member of the family. They also showed a smart shoe equipped with high-resolution pressure sensors that could analyze the wearer’s gait and pick up on any sign of irregularity without needing recharging. It had been designed with the elderly in mind.
The technology itself is no longer the problem; the bottleneck is integration, a lack of connection between different systems, which prevents them from acting in unison without overall management. China’s fifteenth Five-Year Plan was adopted in March, and sets out to obtain a leading strategic position in AI industry applications from 2026 to 2030, with biomedicine recognized as an emerging pillar industry. As of May 2025, the country had released approximately 300 medical large models, and county-level remote medical imaging services had handled more than 68 million cases.
But when it comes to medicine, experts remain cautious. Professor Zhang Wenhong, a prominent Chinese epidemiologist, told the media that AI’s entry into healthcare should complement, not replace, human work. He stressed that investment in people and infrastructure must not be neglected, and that AI should empower medical professionals rather than substitute for them.
This same consideration is, perhaps surprisingly, shared by the actuaries. The actuarial round table ended with a cautious optimism, stating that AI can significantly enhance the efficiency and analytical reach of processes, but that supervision, the ability to interpret results, governance, and human judgment are still required for the proper and effective use of this technology. The panelists also underlined the need for actuarial skills to evolve, with an increased emphasis on data science literacy, ethical reasoning and communication skills.
Conclusion: The Year the Hype Became Infrastructure
Toward the end of 2026, the medical technology, insurance and clinical science sectors find themselves in an unusual position. The experimentation phase is largely over. The question is no longer whether artificial intelligence can work, but whether organizations can integrate it into the systems of financing, medicine and regulation on which patients and doctors depend.
According to last year’s trends, a successful result is not the most visible one. A prior authorization processed in ninety seconds is not a headline; a claim approved without human intervention is not an event of the first magnitude. An oncology patient receiving a follow-up phone call from an artificial intelligence system that has already sorted her symptoms for the nutritionist is not yet a moment to go viral.
But developments like these are the ones that matter: the slow and unglamorous work of making technology reliable enough to be boring, and in medicine boring is often the highest compliment.
IT companies must stop selling chatbots and start offering workflow solutions with a measurable return on investment. For health insurance companies, the priority is to deploy AI into their operations, where the regulatory tailwind is real and the results are auditable. For clinicians and patients, the challenge is to learn to trust systems designed to be invisible, and to demand the transparency and validation that this trust requires.
The revolution, in other words, will not be televised. It will be embedded.
BY GEORGE STAMOS
FOR MORE key data :
- Society of Actuaries (SOA) Roundtable Report: https://www.soa.org/resources/research-reports/2026/ai-healthcare-health-insurance-roundtable/
- Research2Guidance US-EU Insurer AI Adoption Analysis: https://research2guidance.com/health-plan-ai-adoption-why-eu-payers-trail-the-us-and-where-the-white-space-sits-for-healthtech-vendors/
- SCOR AI Assistant Official Case Study: https://www.scor.com/en/download/file?token=def50200c3ae8d1f1e143cb96b8fae3ac6040d726424d93820a9475f227e667ab626be47fdd11a760cec1f614b4ee3882cf5dad630413a209ec3c2fbf69fc20dc25f771a0eb453ebbb00bd8b0297cf0915e48c0ae781cd1b46e9d51421553bdfda09537bcb8d3de5b1b75f1bc1dd51821ba0dc16511aea00215e1daaadc62b1ca6699b41cb#1#1#1